Orr-Walker B J, Evans M C, Ames R W, Clearwater J M, Cundy T, Reid I R
Department of Medicine, University of Auckland, New Zealand.
Clin Endocrinol (Oxf). 1998 Nov;49(5):615-8. doi: 10.1046/j.1365-2265.1998.00582.x.
Depot medroxyprogesterone acetate (DMPA), an injectable progestogen, is a widely used contraceptive acting primarily by inhibiting secretion of pituitary gonadotrophins, thus producing oestrogen deficiency. Cross-sectional and prospective studies in pre-menopausal women have shown DMPA use to be associated with reduced bone density, but bone density increases following discontinuation of the drug. Because fracture rates are low in pre-menopausal women, the principal concern arising from the effects of DMPA on bone is that there may be residual osteopenia in former users such that their post-menopausal fracture risk is increased. The present study addresses this question.
Cross-sectional study of bone density in post-menopausal former users of DPMA and controls.
Three hundred and forty-six normal post-menopausal women, of whom 34 had previously used DMPA. The median age at which DMPA use began was 41 years and the median duration of use was 3.0 years.
Bone density was measured in the spine, proximal femur and total body by dual-energy, X-ray absorptiometry.
There were no significant differences in bone density at any site between the women who had previously used DMPA and the others in the cohort. However, in those who had used DMPA for > 2 years there was a trend towards bone densities being lower in the former users, the differences from non-users being 1.6% in the lumbar spine (P = 0.6), 3.1% in the femoral neck (P = 0.4) and 0.5% in the total body (P = 0.8). There was no correlation between bone densities and the duration of DMPA use, the age at discontinuation of DMPA, or the time between DMPA discontinuation and the menopause.
Any residual effects of depot medroxyprogesterone acetate use on post-menopausal bone density are small and therefore unlikely to have a substantial impact on fracture risk in the post-menopausal years.
醋酸甲羟孕酮长效注射剂(DMPA)是一种广泛使用的孕激素,主要通过抑制垂体促性腺激素的分泌发挥作用,从而导致雌激素缺乏。对绝经前女性的横断面研究和前瞻性研究表明,使用DMPA与骨密度降低有关,但停药后骨密度会增加。由于绝经前女性的骨折发生率较低,DMPA对骨骼影响引发的主要担忧是,既往使用者可能存在残余骨质减少,从而增加其绝经后骨折风险。本研究探讨了这一问题。
对绝经后DMPA既往使用者和对照组进行骨密度横断面研究。
346名正常绝经后女性,其中34人曾使用过DMPA。开始使用DMPA的中位年龄为41岁,中位使用时间为3.0年。
采用双能X线吸收法测量脊柱、股骨近端和全身的骨密度。
既往使用DMPA的女性与队列中的其他女性在任何部位的骨密度均无显著差异。然而,在使用DMPA超过2年的女性中,既往使用者的骨密度有降低趋势,与未使用者相比,腰椎降低1.6%(P = 0.6),股骨颈降低3.1%(P = 0.4),全身降低0.5%(P = 0.8)。骨密度与DMPA使用时间、停药年龄或停药至绝经的时间之间无相关性。
醋酸甲羟孕酮长效注射剂使用对绝经后骨密度的任何残余影响都很小,因此不太可能对绝经后几年的骨折风险产生实质性影响。